| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 481,281 | 101,019 | ||
| Prepaid expenses | 100,000 | - | ||
| Deposits | 16,942 | 16,942 | ||
| Total current assets | 598,223 | 117,961 | ||
| Property and equipment, net of accumulated depreciation of 757 and 2,256 | 2,049 | 2,304 | ||
| Right of use - asset | 11,211 | 27,670 | ||
| Intangible assets - acquired patents and license, net of amortization | 15,920,319 | 20,694,893 | ||
| Total non-current assets | 15,933,579 | 20,724,867 | ||
| Total assets | 16,531,802 | 20,842,828 | ||
| Accounts payable and accrued liabilities | 526,964 | 767,996 | ||
| Accrued liabilities - related parties | - | 30,000 | ||
| Payroll tax liabilities | 4,460 | 2,973 | ||
| Notes payable-Nonrelated Party | - | 500,000 | ||
| Notes payable-Related Party | 100,000 | 100,000 | ||
| Right-of-use liability - operating lease | 12,167 | 30,117 | ||
| Other liabilities-Patent Purchase Payable | 160,684 | 160,684 | ||
| Other liabilities-Related Party | - | 9,175 | ||
| Total current liabilities | 804,275 | 1,600,945 | ||
| Total liabilities | 804,275 | 1,600,945 | ||
| Preferred stock, value-Series CConvertible Preferred Stock | 98 | 98 | ||
| Common stock (par value 0.0001), 200,000,000 shares authorized, of which 13,883,103 and 3,245,641 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 1,389 | 1,065 | ||
| Stock warrants | 324,288 | 324,288 | ||
| Subscriptions receivable | - | 224,569 | ||
| Additional paid in capital | 53,283,483 | 50,794,020 | ||
| Accumulated deficit | -37,877,913 | -31,649,804 | ||
| Accumulated other comprehensive loss | -2,079 | -2,034 | ||
| Stockholders Equity | 15,729,266 | 19,243,064 | ||
| Non-controlling interest | -1,739 | -1,181 | ||
| Total stockholders equity | 15,727,527 | 19,241,883 | ||
| Total liabilities and stockholders equity | 16,531,802 | 20,842,828 | ||
MANGOCEUTICALS, INC. (MGRX)
MANGOCEUTICALS, INC. (MGRX)